Subsidiaries & Affiliates
At Bukwang, our unique network of subsidiaries, joint-venture affiliates,
collaborative partnerships, and investee alliances empowers us to
embark on a diverse array of initiatives aimed at bolstering our pipeline,
securing development and marketing rights, discovering and developing
new drug candidates, and catalyzing the growth of innovative ventures.
-
CONTERA PHARMA A/S
Established in 2010 by former researchers from Novo Nordisk and Novartis,
Contera Pharma, a Copenhagen-based clinical-stage company, specializes in
developing treatments for neurological disorders. At the forefront of Contera's
portfolio is JM-010, currently in clinical development as an innovative treatment
for dyskinesia in Parkinson's disease. We acquired a 100% equity stake in Contera
in November 2014, and as of 2023, our stake stands at an impressive 72.84%,
underscoring our unwavering commitment to advancing innovative solutions in t
he field of neurological therapeutics.
-
DYNA THERAPEUTICS
Established in 2016, Dyna exclusively licensed global development and
commercialization rights for SOL-804, a treatment for metastatic prostate
cancer from a Danish firm Solural Pharma in June of the same year.
As of 2023, our stake at Dyna stood at 98.84%.
-
BUKWANG MEDICA
Founded in June 2015, Bukwang Medica is a wholly owned subsidiary that
handles the sales and distribution of our growing nutraceutical product
lineup under the Bukwang Lab brand.
-
PROTEKT THERAPEUTICS
Founded in 2019, Protekt Therapeutics is an Israeli biotech company aiming to
develop potent and selective oral inhibitors of the kinase PKR for the treatment of
neurodegenerative and neuroinflammatory diseases. ProteKt has discovered and
developed a series of novel and selective molecules by applying unique
computational methods and validating the inhibitors in clinically relevant assays.
-
JAGUAHR THERAPETICS
JaguAhR is a Singapore-based joint venture with Aslan Pharmaceuticals focused
on developing novel immuno-oncology therapeutics targeting the aryl
hydrocarbon receptor (AhR) pathway. We hold a 65% equity stake in the biotech.